Literature DB >> 22982018

Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats.

Jun Zhang1, Chang-Yin Li, Mei-juan Xu, Ting Wu, Ji-Hong Chu, Shi-Jia Liu, Wen-Zheng Ju.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Celastrol is a natural compound extracted from the traditional Chinese medicinal herb, Thunder God Vine (TGV). Owing to its potential anti-inflammatory and antitumor effects, celastrol has been considered as a promising candidate for drug development. AIM OF THE STUDY: To establish a sensitive LC-MS/MS method to investigate the pharmacokinetic properties of celastrol in rats. Key pharmacokinetic issues of celastrol including oral bioavailability, comparative pharmacokinetics between pure compound and tablet preparation, as well as gender-related pharmacokinetic difference are to be addressed for the first time.
MATERIALS AND METHODS: Sprague-Dawley rats were administrated an intravenous dose (100 μg kg(-1)) of pure celastrol and an oral dose (1000 μg kg(-1)) of pure celastrol and TGV tablets (corresponding to 534 μg kg(-1) of celastrol), respectively. At different time points, the concentration of celastrol in rat plasma was determined by a sensitive and well-validated LC-MS/MS method. Main pharmacokinetic parameters including area under the plasma concentration-time curve (AUC), maximal plasma concentration (Cmax), the time for maximal concentration (Tmax) and mean residence time (MRT) were estimated by Drug and Statistic1.0 pharmacokinetic software (Chinese Pharmacological Association, Anhui, PR China). Statistical analysis was performed using two one-side t test with p-values less than 0.05 as the level of significance.
RESULTS: The standard curve of celastrol showed good linearity in the concentration range of 0.11~54.3 ng mL(-1) in our current method, with acceptable selectivity, precision, recovery, and stability. The oral absolute bioavailability of celastrol significantly increased from 17.06% for pure celastrol to 94.19% for TGV tablets containing equivalent celastrol. After oral administration of TGV tablets, the Cmax and AUC values of celastrol in female rats were (32.03±8.41) μg L(-1) and (379.49±118.19) μg h L(-1), which were significantly higher (p<0.01) than that in males with the values of (14.31±7.33) μg L(-1) and (188.17±92.33) μg h L(-1).
CONCLUSION: Celastrol administered orally in the rat was poorly absorbed into the systemic circulation. However, the poor absorption of celastrol could be greatly improved when celastrol-containing TGV tablets orally administered, and thereby the oral bioavailability of celastrol was significantly increased. As for gender difference, female rats showed significantly better absorption of celastrol than males.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982018     DOI: 10.1016/j.jep.2012.09.005

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  22 in total

1.  Celastrol prevents cadmium-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.

Authors:  Sujuan Chen; Chenjian Gu; Chong Xu; Jinfei Zhang; Yijiao Xu; Qian Ren; Min Guo; Shile Huang; Long Chen
Journal:  J Neurochem       Date:  2013-10-24       Impact factor: 5.372

2.  Celastrol protects ischaemic myocardium through a heat shock response with up-regulation of haeme oxygenase-1.

Authors:  S Der Sarkissian; J-F Cailhier; M Borie; L-M Stevens; L Gaboury; S Mansour; P Hamet; N Noiseux
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  Celastrol prevents cadmium-induced neuronal cell death by blocking reactive oxygen species-mediated mammalian target of rapamycin pathway.

Authors:  Ruijie Zhang; Nana Zhang; Hai Zhang; Chunxiao Liu; Xiaoqing Dong; Xiaoxue Wang; Yu Zhu; Chong Xu; Lei Liu; Sijun Yang; Shile Huang; Long Chen
Journal:  Br J Pharmacol       Date:  2016-11-21       Impact factor: 8.739

4.  Potent suppression of both spontaneous and carcinogen-induced colitis-associated colorectal cancer in mice by dietary celastrol supplementation.

Authors:  Emily C Barker; Byung-Gyu Kim; Ji Hee Yoon; Gregory P Tochtrop; John J Letterio; Sung Hee Choi
Journal:  Carcinogenesis       Date:  2018-01-12       Impact factor: 4.944

5.  Native Endophytes of Tripterygium wilfordii-Mediated Biotransformation Reduces Toxicity of Celastrol.

Authors:  Ping-Yang Ma; Wei-Ling Geng; Hong-Yan Ji; Bang-Wen Yue; Cheng Liu; Sa Wang; Zhi-Bo Jiang; Jing Chen; Xiu-Li Wu
Journal:  Front Microbiol       Date:  2022-05-25       Impact factor: 6.064

6.  Celastrol-loaded PEG-b-PPS nanocarriers as an anti-inflammatory treatment for atherosclerosis.

Authors:  Sean D Allen; Yu-Gang Liu; Taehyeung Kim; Sharan Bobbala; Sijia Yi; Xiaohan Zhang; Jaehyuk Choi; Evan A Scott
Journal:  Biomater Sci       Date:  2019-01-29       Impact factor: 6.843

7.  Celastrol Dilates and Counteracts Ethanol-Induced Constriction of Cerebral Arteries.

Authors:  Kelsey North; Alexandria Slayden; Steven Mysiewicz; Anna Bukiya; Alex Dopico
Journal:  J Pharmacol Exp Ther       Date:  2020-08-29       Impact factor: 4.030

8.  Celastrol, an oral heat shock activator, ameliorates multiple animal disease models of cell death.

Authors:  Sudhish Sharma; Rachana Mishra; Brandon L Walker; Savitha Deshmukh; Manuela Zampino; Jay Patel; Mani Anamalai; David Simpson; Ishwar S Singh; Shalesh Kaushal; Sunjay Kaushal
Journal:  Cell Stress Chaperones       Date:  2014-10-11       Impact factor: 3.667

9.  Deficiency in Duox2 activity alleviates ileitis in GPx1- and GPx2-knockout mice without affecting apoptosis incidence in the crypt epithelium.

Authors:  Fong-Fong Chu; R Steven Esworthy; James H Doroshow; Helmut Grasberger; Agnes Donko; Thomas L Leto; Qiang Gao; Binghui Shen
Journal:  Redox Biol       Date:  2016-11-22       Impact factor: 11.799

10.  Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats.

Authors:  Rita Cascão; Bruno Vidal; Inês P Lopes; Eunice Paisana; José Rino; Luis F Moita; João E Fonseca
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.